alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL  INFORMATION  EXTRACTED
FROM THE AUDITED DECEMBER 31, 1996 BALANCE  SHEET  AND STATEMENT OF
OPERATIONS OF FORCENERGY INC  FOR THE FISCAL YEAR ENDED DECEMBER 31,
1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
/LEGEND>
       
<S>                                             <C>
<PERIOD-TYPE>                                   12-MOS
<FISCAL-YEAR-END>                               DEC-31-1996
<PERIOD-END>                                    DEC-31-1996
<CASH>                                             9,669
<SECURITIES>                                           0
<RECEIVABLES>                                     29,416
<ALLOWANCES>                                           0
<INVENTORY>                                            0
<CURRENT-ASSETS>                                  10,673
<PP&E>                                           523,711
<DEPRECIATION>                                         0
<TOTAL-ASSETS>                                   585,925
<CURRENT-LIABILITIES>                             43,013
<BONDS>                                          272,932
<PREFERRED-MANDATORY>                                  0
<PREFERRED>                                            0
<COMMON>                                             226
<OTHER-SE>                                       248,710
<TOTAL-LIABILITY-AND-EQUITY>                     585,925
<SALES>                                          138,698
<TOTAL-REVENUES>                                 139,381
<CGS>                                                  0
<TOTAL-COSTS>                                    108,675
<OTHER-EXPENSES>                                    (650)
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                13,367
<INCOME-PRETAX>                                   17,989
<INCOME-TAX>                                       6,711
<INCOME-CONTINUING>                                    0
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                      11,278
<EPS-PRIMARY>                                        .57
<EPS-DILUTED>                                        .62
        

</TABLE>
#### § 507.125 Determining appropriate supplier verification activities (including determining the frequency of conducting the activity).

Appropriate supplier verification activities (including the frequency of conducting the activity) must be determined in accordance with the requirements of § 507.110(d).
# L_2018307EN.01002201.xml

| 3.12.2018 | EN | Official Journal of the European Union | L 307/22 |
| --- | --- | --- | --- |

3.12.2018

EN

Official Journal of the European Union

L 307/22

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1878

of 26 November 2018

entering a name in the register of protected designations of origin and protected geographical indications (‘Scrumbie de Dunăre afumată’ (PGI))

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (1), and in particular Article 52(2) thereof,

Whereas:

| (1) | Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Romania's application to register the name ‘Scrumbie de Dunăre afumată’ was published in the Official Journal of the European Union (2). |
| --- | --- |

(1)

Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Romania's application to register the name ‘Scrumbie de Dunăre afumată’ was published in the Official Journal of the European Union (2).

| (2) | As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Scrumbie de Dunăre afumată’ should therefore be entered in the register, |
| --- | --- |

(2)

As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Scrumbie de Dunăre afumată’ should therefore be entered in the register,

HAS ADOPTED THIS REGULATION:

Article 1

The name ‘Scrumbie de Dunăre afumată’ (PGI) is hereby entered in the register.

The name specified in the first paragraph denotes a product in Class 1.7. — Fresh fish, molluscs and crustaceans and products derived therefrom, as listed in Annex XI to Commission Implementing Regulation (EU) No 668/2014 (3).

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 26 November 2018.

For the Commission,

On behalf of the President,

Phil HOGAN

Member of the Commission

---

(1)  
  OJ L 343, 14.12.2012, p. 1.

1

(2)  
  OJ C 162, 8.5.2018, p. 28.

2

(3)  Commission Implementing Regulation (EU) No 668/2014 of 13 June 2014 laying down rules for the application of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs (OJ L 179, 19.6.2014, p. 36).

3

---
**Exhibit
      32.1**








**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**











In
      connection with the Annual Report of Astea International Inc. (the “Company”) on
      Form 10-K for the period ending December 31, 2006 as filed with the Securities
      and Exchange Commission on the date hereof (the “Report”), I, Zack Bergreen,
      Chief Executive Officer and Principal Executive Officer of the Company, certify,
      pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley
      Act of 2002, that:





|(1) | The
              Report fully complies with the requirements of section 13(a) or 15(d)
              of
              the Securities Exchange Act of 1934; and
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------




|(2) | The
              information contained in the Report fairly presents, in all material
              respects, the financial condition and results of operations of the
              Company.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




/s/ 
                Zack BergreenZack
                BergreenChief
                Executive Officer(Principal
                Executive Officer)April
                2, 2007
1 

### Gurdoglanyan, Nicole

From: Regla Perez Pino [rperezpino@gmail.com] Sent: Friday, May 04, 2012 6:30 AM To: GovernmentAffairs Subject: SJU- DCA Non-stop Re: Docket No. DOT-OST-2012-0029

Re: Docket No. DOT-OST-2012-0029 Dear Secretary LaHood:

I am writing today to express my strong suppor t for JetBlue’s application to offer new beyond- p erimeter service at Reagan National and link the nation’s capital to two other important c apital cities: San Juan, Puerto Rico (connecting onward to St. Thomas, the capital of the U.S. Virgin Islands) and Austin, Texas.

JetBlue’s application will provide much-needed low-fare, high-qua lity service from the capital’s downtown airport to the capital of our closest territory, and to the capital of the larg est of the contiguous 48 states. Both San Juan and Austin are crying out for new JetBlue service to DCA, being two of the ten largest markets without nonstop air service to the airport. Their application will bring tremendous public benefit and much-needed low-fare competition to DCA.

Please join me in offering your support for JetBlue’s application.

Regla Perez Pino

Alexandria, VA

rperezpino@gmail.com
**UN PUBLISHED** 
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

**No. 14**  **- 4604** 

UNITED STATES OF AMERICA , Plaintiff

- Appellee ,
v. DONTE LEE SMITH , Defendant

- Appellant
.

Appeal from the United States District Court for the Middle District of North Carolina , at Greensboro
. Catherine C. Eagles , District Judge. ( 1:14

- cr - 00017

- CCE

- 1 )

Submitted : February 25, 2015 Decided: March 3, 2015

Before NIEMEYER, KING, and THACKER , Circuit Judges.

Affirmed by un published per curiam opinion
. Louis C. Allen, Federal Public Defender, Tiffany T. Jefferson, Assistant Federal Public Defender, Greensboro, North Carolina, for Appellant. Kyle David Pousson, OFFICE OF THE UNITED STATES ATTORNEY, Greensboro, North Carolina, for Appellee.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Donte Lee Smith appeals his eighty

- month sentence imposed after he pled guilty pursuant to a plea agreement to
p ossession of a mmunition by a f elon , in violation of 18 U.S.C. §§ 92 2(g)(1) , 924(a)(2) (2012). In accordance with Anders v. California , 386 U.S. 738 (1967), Smith’s counsel filed a brief certifying that there are no meritorious grounds for appeal , but questioning whether Smith’s sentence is substantively reasonable. Alth ough notified of his right to do so, Smith has not filed a pro se supplemental brief , and the Government has declined to file a responsive brief. Finding no error, w e affirm. We review the district court’ s sentence, “whether inside, just outside, or signi ficantly outside the Guidelines range[,] under a deferential abuse

- of

- discretion standard.” Gall v. United States , 552 U.S. 38, 41 (2007). In reviewing a sentence for substantive reasonableness, we “examine[] the totality of the circumstances,” and, if the sentence is within the properly calculated Guidelines range, we presume on appeal that the sentence is substantively reasonable. United S tates v. Mendoza

– Mendoza , 597 F.3d 212, 216

– 17 (4th Cir. 2010). “ Such a presumption can only be rebutted by showing that the sentence is unreasonable when measured against the 18 U.S.C. § 3553(a) [(2012)] factors. ” United States v. Louthian , 756 F.3d 295 , 3063 (4th Cir.) (citations omitted), cert. denied , 135 S. Ct. 421 (2014). Smith has failed to rebut the presumption of reasonableness this court affords his within

- Guidelines
sentence. In accordance with Anders , we have reviewed the entire record and h ave found no meritorious grounds for appeal. We therefore affirm the district court ’ s judgment. This court requires that counsel inform Smith , in writing, of his right to petition the Supreme Court of the United States for further review. If Smith reque sts that a petition be filed, but counsel believes that such a petition would be frivolous, counsel may move in this court for leave to withdraw from representation. Counsel’ s motion must state that a copy thereof was served on Smith
. We dispense with or al argument because the facts and legal contentions are adequately presented in the materials before this court and argument would not aid the decisional
process.

AFFIRMED
###### Editorial Note on Part 369

#### Editorial Note:

Nomenclature changes to part 369 appear at 69 FR 13717, Mar. 24, 2004.

#### § 369.9 General warnings re accidental ingestion by children.

Section 369.20 includes under certain items, but not all medicines, the statement: “Keep this and all medicines out of children's reach. In case of overdose, get medical help or contact a Poison Control Center right away,” or “Keep out of reach of children.” However, in view of the possibility of accidental ingestion of drugs, it is not only suggested but is recommended that one of these statements be used on the label of all drug products.

[64 FR 13296, Mar. 17, 1999]
PDF Upload 3/1/98:  Humanitarian Resource Institute

    -       - Superintendent of Documents
      - 2023-12-07T10:56:16-0500
      - Government Publishing Office, Washington, DC 20401
      - Government Publishing Office
      - Government Publishing Office attests that this document has not been altered since it was disseminated by Government Publishing Office
§ 516.1449 Molidustat oral suspension. ( a ) *Specifications.* Each milliliter (mL) of suspension contains 25 milligrams (mg) molidustat sodium.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer orally at a dosage of 5 mg/kg of body weight (2.3 mg/lb) daily for up to 28 consecutive days.
( 2 ) *Indications for use.* For the control of nonregenerative anemia associated with chronic kidney disease in cats.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
[88 FR 55563, Aug. 16, 2023]
§ 520.2345e Tetracycline solution. ( a ) *Specifications.* Each milliliter contains the equivalent of either 25 or 100 milligrams of tetracycline hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 25 milligrams per pound of body weight per day in divided doses every 6 hours.
( ii ) *Indications for use.* Treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to *Escherichia coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli.*
( iii ) *Limitations.* Administer orally; continue treatment until symptoms have subsided and the temperature is normal for 48 hours; not for use in animals which are raised for food production; Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Dogs and cats* — ( i ) *Amount.* 25 milligrams per pound of body weight per day in divided doses every 6 hours.
( ii ) *Indications for use.* Treatment of infections caused by organisms susceptible to tetracycline hydrochloride, such as bacterial gastroenteritis due to *E. coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli.*
( iii ) *Limitations.* Administer orally; continue treatment until the temperature has been normal for 48 hours; not for use in food-producing animals; Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37329, Aug. 18, 1992, as amended at 79 FR 28831, May 20, 2014]
EX-10.2a



 Exhibit 10.2(a) 

FIRST LIEN SECURITY AGREEMENT SUPPLEMENT 

August 22, 2014 
 Reference
is hereby made to that certain First Lien Security Agreement, dated as of July 25, 2014 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “First Lien Security Agreement”) among
Advantage Sales & Marketing Inc. (as successor-in-interest to Karman Buyer Corp.), a Delaware corporation (the “Borrower”), Karman Intermediate
Corp., a Delaware corporation, the Subsidiary Guarantors party thereto and Bank of America, N.A., as Collateral Agent. Unless otherwise defined herein, capitalized terms defined in the First Lien Security Agreement Agreement and used herein shall
have the meanings given to them in the First Lien Security Agreement. 
 The undersigned, in his capacity as a Responsible Officer of
Borrower, hereby certifies, on behalf of Borrower and not in his individual or personal capacity and without personal liability, that, as of the date hereof, the information below, in addition to information delivered to the the Collateral Agent on
or prior to the date hereof supplements certain information described in the First Lien Security Agreement delivered on the Closing Date: 

SUPPLEMENT TO SCHEDULE II TO SECURITY AGREEMENT 

PLEDGED EQUITY; PLEDGED DEBT 
  

													
	 Grantor
	  	 Current Legal

Owned Entities
	  	 Type of

Organization
	  	Certificate
No.	  	No. of
Shares/Interest
Issued	  	No. Shares/
Interest
Owned	 	Percent
of Owned
Interest
Pledged
	 Advantage Sales & Marketing Inc.
	  	Advantage Consumer Healthcare LLC	  	Limited Liability Company	  	N/A	  	N/A	  	100%	 	100%

 [Signature page follows] 

  
 1 








 IN WITNESS WHEREOF, the undersigned has caused this Security Agreement Supplement to be executed
as of the date first above written by its officer thereunto duly authorized. 
  

			
	ADVANTAGE SALES & MARKETING, INC.
		
	By:	 	 /s/ Robert Murray

	Name:	 	Robert Murray
	Title:	 	Treasurer
Exhibit 15.1




Consent of Independent Registered Public Accounting Firm




We consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-102288 and 333-92491) pertaining to the Stock Option plans of Ellomay Capital Ltd. and on Form F-3 (File Nos. 333-144171, 333-115826, 333-114428, 333-47842 and 333-92493) of Ellomay Capital Ltd. our report dated April 5, 2012, with respect to the consolidated financial statements of Ellomay Capital Ltd. and its subsidiaries included in this Annual Report on Form 20-F for the year ended December 31, 2011.





/s/ Somekh Chaikin

Somekh Chaikin



Certified Public Accountants (Isr).

Member firmof KPMG International



Tel-Aviv, Israel



April 5, 2012
§ 350.10 Antiperspirant active ingredients. The active ingredient of the product consists of any of the following within the established concentration and dosage formulation. Where applicable, the ingredient must meet the aluminum to chloride, aluminum to zirconium, and aluminum plus zirconium to chloride atomic ratios described in the U.S. Pharmacopeia-National Formulary. The concentration of ingredients in paragraphs (b) through (j) of this section is calculated on an anhydrous basis, omitting from the calculation any buffer component present in the compound, in an aerosol or nonaerosol dosage form. The concentration of ingredients in paragraphs (k) through (r) of this section is calculated on an anhydrous basis, omitting from the calculation any buffer component present in the compound, in a nonaerosol dosage form. The labeled declaration of the percentage of the active ingredient should exclude any water, buffer components, or propellant. ( a ) Aluminum chloride up to 15 percent, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form.
( b ) Aluminum chlorohydrate up to 25 percent.
( c ) Aluminum chlorohydrex polyethylene glycol up to 25 percent.
( d ) Aluminum chlorohydrex propylene glycol up to 25 percent.
( e ) Aluminum dichlorohydrate up to 25 percent.
( f ) Aluminum dichlorohydrex polyethylene glycol up to 25 percent.
( g ) Aluminum dichlorohydrex propylene glycol up to 25 percent.
( h ) Aluminum sesquichlorohydrate up to 25 percent.
( i ) Aluminum sesquichlorohydrex polyethylene glycol up to 25 percent.
( j ) Aluminum sesquichlorohydrex propylene glycol up to 25 percent.
( k ) Aluminum zirconium octachlorohydrate up to 20 percent.
( l ) Aluminum zirconium octachlorohydrex gly up to 20 percent.
( m ) Aluminum zirconium pentachlorohydrate up to 20 percent.
( n ) Aluminum zirconium pentachlorohydrex gly up to 20 percent.
( o ) Aluminum zirconium tetrachlorohydrate up to 20 percent.
( p ) Aluminum zirconium tetrachlorohydrex gly up to 20 percent.
( q ) Aluminum zirconium trichlorohydrate up to 20 percent.
( r ) Aluminum zirconium trichlorohydrex gly up to 20 percent.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE CONDENSED CONSOLIDATED BALANCE SHEETS AND THE CONDENSED STATEMENTS OF
OPERATIONS FOUND ON PAGES F-3 AND F-4 OF THE COMPANY'S FORM 10-K FOR THE TWELVE
MONTHS ENDED JULY 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<PERIOD-TYPE>                                 12-MOS
<FISCAL-YEAR-END>                          JUL-31-1996
<PERIOD-END>                               JUL-31-1996
<CASH>                                         531,040
<SECURITIES>                                         0
<RECEIVABLES>                               30,928,187
<ALLOWANCES>                                 1,621,603
<INVENTORY>                                 44,437,694
<CURRENT-ASSETS>                            78,009,327
<PP&E>                                      16,941,214
<DEPRECIATION>                               1,811,028
<TOTAL-ASSETS>                             103,912,914
<CURRENT-LIABILITIES>                       53,736,980
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,000
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>               103,912,914
<SALES>                                     74,197,301
<TOTAL-REVENUES>                            74,197,301
<CGS>                                       50,049,224
<TOTAL-COSTS>                               50,049,224
<OTHER-EXPENSES>                            17,471,966
<LOSS-PROVISION>                             1,163,346
<INTEREST-EXPENSE>                             660,135
<INCOME-PRETAX>                              6,671,764
<INCOME-TAX>                                 2,619,649
<INCOME-CONTINUING>                          4,052,115
<DISCONTINUED>                               (384,038)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 3,668,077
<EPS-PRIMARY>                                      .76
<EPS-DILUTED>                                      .76


</TABLE>
§ 2.5 Imminent hazard to the public health. ( a ) Within the meaning of the Federal Food, Drug, and Cosmetic Act an imminent hazard to the public health is considered to exist when the evidence is sufficient to show that a product or practice, posing a significant threat of danger to health, creates a public health situation ( 1 ) that should be corrected immediately to prevent injury and
( 2 ) that should not be permitted to continue while a hearing or other formal proceeding is being held. The *imminent hazard* may be declared at any point in the chain of events which may ultimately result in harm to the public health. The occurrence of the final anticipated injury is not essential to establish that an *imminent hazard* of such occurrence exists.
( b ) In exercising his judgment on whether an *imminent hazard* exists, the Commissioner will consider the number of injuries anticipated and the nature, severity, and duration of the anticipated injury.